David A. Siegel Vanda Pharmaceuticals Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 703,900 shares of VNDA stock, worth $3.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
703,900
Previous 886,500
20.6%
Holding current value
$3.6 Million
Previous $3.74 Million
22.67%
% of portfolio
0.01%
Previous 0.01%
Shares
27 transactions
Others Institutions Holding VNDA
# of Institutions
147Shares Held
49.6MCall Options Held
49.1KPut Options Held
107K-
Black Rock Inc. New York, NY8.14MShares$41.6 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.28MShares$21.8 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.4MShares$17.4 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.37MShares$12.1 Million0.03% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.8MShares$9.21 Million0.01% of portfolio
About Vanda Pharmaceuticals Inc.
- Ticker VNDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,561,500
- Market Cap $289M
- Description
- Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...